Annals of Oncology 8:583-592, 1997
© 1997 European Society for Medical Oncology
research-article |
Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification
1Service of Pathologic Anatomy and Unit of Hematopathology - Institute of Hematology and Clinical Oncology ‘L & A. Seràgnoli’- Bologna University Italy
2Department of Pediatric Oncology, Bologna University Italy
3Institute of Pathologic Anatomy and Histopathology, Siena University Italy
4Institute of Hematology, Perugia University Italy
Correspondence to: Prof. Dr. Stefano A. Pileri Servizio di Anatomia e Istologia Patologica Sezione di Istologia Emolinfopatologica Istituto di Ematologia ed Oncologia Medica L & A Seragnoli, Universitá di Bologna Policlinico S. Orsola Via Massarenti 9 1-40138 Bologna Italy
BACKGROUND: One hundred sixty-eight peripheral T-cell lymphomas (PTCLs) were reviewed according to the Revised European-American Lymphoma (R.E.A.L.) Classification.
PATIENTS AND METHODS: The cases, originally diagnosed on the basis of the Updated Kiel Classification (UKC), were all provided with histological preparations, immunophenotype, clinical information, and follow-up data. The slides were reclassified by five observers, who integrated the R.E.A.L criteria with cell size measurements. The prognostic value of clinical and pathologic findings was assessed by univariate and multivariate analysis.
RESULTS: The R.E.A.L. Classification was reproducibly applied by all of the observers. Clinically, anaplastic large cell lymphomas (ALCLs) differed from the remaining PTCLs by mean age (29.5 vs. 52.9 years), bulky disease (52.3% vs. 11.3%; P = 0.000), mediastinal mass (52.7% vs. 32%; P = 0.004), and disease-free survival (68.0% vs. 38.2%; P = 0.0001). Although each histological type displayed specific clinical aspects, PTCLs other than ALCL were basically characterised by a poor clinical outcome which was not influenced by the UKC malignancy grade. At multivariate analysis, the risk of a lower complete remission rate was related to bulky disease (P =0.001), histologic group (non-ALCL) (P = 0.01), and advanced stage (III–IV) (P – 0.0002).
CONCLUSIONS: The present study supports the classification of T-cell lymphomas proposed by the R.E.A.L. scheme.
anaplastic large cell lymphoma, classification, clinics, histology, immunohistochemistry, peripheral T-cell lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study J. Clin. Oncol., January 1, 2009; 27(1): 106 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Vose The International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: What Have We Learned? ASCO Educational Book, January 1, 2009; 2009(1): 490 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies J. Clin. Pathol., November 1, 2008; 61(11): 1160 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
International T-Cell Lymphoma Project International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes J. Clin. Oncol., September 1, 2008; 26(25): 4124 - 4130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma Ann. Onc., May 1, 2008; 19(5): 958 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Piccaluga, C. Agostinelli, A. Califano, A. Carbone, L. Fantoni, S. Ferrari, A. Gazzola, A. Gloghini, S. Righi, M. Rossi, et al. Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation Cancer Res., November 15, 2007; 67(22): 10703 - 10710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood, October 1, 2007; 110(7): 2316 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study Blood, December 15, 2006; 108(13): 4163 - 4169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Went, C. Agostinelli, A. Gallamini, P. P. Piccaluga, S. Ascani, E. Sabattini, F. Bacci, B. Falini, T. Motta, M. Paulli, et al. Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score J. Clin. Oncol., June 1, 2006; 24(16): 2472 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishida, H. Inagaki, A. Utsunomiya, Y. Takatsuka, H. Komatsu, S. Iida, G. Takeuchi, T. Eimoto, S. Nakamura, and R. Ueda CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified Clin. Cancer Res., August 15, 2004; 10(16): 5494 - 5500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood, April 1, 2004; 103(7): 2474 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S A Pileri, S Ascani, L Leoncini, E Sabattini, P L Zinzani, P P Piccaluga, A Pileri Jr, M Giunti, B Falini, G B Bolis, et al. Hodgkin's lymphoma: the pathologist's viewpoint J. Clin. Pathol., March 1, 2002; 55(3): 162 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Rudiger, D. D. Weisenburger, J. R. Anderson, J. O. Armitage, J. Diebold, K. A. MacLennan, B. N. Nathwani, F. Ullrich, and H. K. Muller-Hermelink Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project Ann. Onc., January 19, 2002; 13(1): 140 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fournel-Fleury, F. Ponce, P. Felman, A. Blavier, C. Bonnefont, L. Chabanne, T. Marchal, J. L. Cadore, I. Goy-Thollot, D. Ledieu, et al. Canine T-cell Lymphomas: A Morphological, Immunological, and Clinical Study of 46 New Cases Vet. Pathol., January 1, 2002; 39(1): 92 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Zinzani, G. Baliva, M. Magagnoli, M. Bendandi, G. Modugno, F. Gherlinzoni, G. F. Orcioni, S. Ascani, R. Simoni, S. A. Pileri, et al. Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients J. Clin. Oncol., July 1, 2000; 18(13): 2603 - 2606. [Abstract] [Full Text] [PDF]
|
|